Birchview Capital LP Makes New Investment in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

Birchview Capital LP purchased a new position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 16,000 shares of the biopharmaceutical company's stock, valued at approximately $673,000. Ultragenyx Pharmaceutical makes up about 0.5% of Birchview Capital LP's portfolio, making the stock its 27th largest holding.

Other institutional investors have also modified their holdings of the company. Smartleaf Asset Management LLC lifted its position in Ultragenyx Pharmaceutical by 259.5% in the fourth quarter. Smartleaf Asset Management LLC now owns 683 shares of the biopharmaceutical company's stock valued at $29,000 after acquiring an additional 493 shares during the last quarter. Aster Capital Management DIFC Ltd purchased a new stake in Ultragenyx Pharmaceutical in the fourth quarter valued at $35,000. Human Investing LLC purchased a new stake in Ultragenyx Pharmaceutical in the fourth quarter valued at $42,000. Wilmington Savings Fund Society FSB acquired a new position in Ultragenyx Pharmaceutical in the third quarter valued at $83,000. Finally, Van ECK Associates Corp increased its stake in Ultragenyx Pharmaceutical by 18.4% in the fourth quarter. Van ECK Associates Corp now owns 1,760 shares of the biopharmaceutical company's stock valued at $74,000 after purchasing an additional 273 shares during the period. Institutional investors and hedge funds own 97.67% of the company's stock.

Analyst Ratings Changes

A number of research analysts have commented on RARE shares. Wedbush restated a "neutral" rating and issued a $48.00 price objective (up from $46.00) on shares of Ultragenyx Pharmaceutical in a research note on Monday, January 13th. Canaccord Genuity Group lifted their price objective on Ultragenyx Pharmaceutical from $121.00 to $136.00 and gave the stock a "buy" rating in a report on Tuesday, February 18th. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $118.00 price objective on shares of Ultragenyx Pharmaceutical in a report on Wednesday, February 26th. HC Wainwright reissued a "buy" rating and issued a $95.00 price target on shares of Ultragenyx Pharmaceutical in a report on Friday, February 14th. Finally, Piper Sandler lowered their price target on Ultragenyx Pharmaceutical from $140.00 to $115.00 and set an "overweight" rating for the company in a research report on Monday, March 17th. One equities research analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the company's stock. According to MarketBeat.com, Ultragenyx Pharmaceutical has a consensus rating of "Moderate Buy" and an average price target of $92.79.

Insider Buying and Selling at Ultragenyx Pharmaceutical

In related news, EVP Karah Herdman Parschauer sold 2,990 shares of the stock in a transaction that occurred on Thursday, February 27th. The stock was sold at an average price of $42.88, for a total transaction of $128,211.20. Following the completion of the transaction, the executive vice president now directly owns 54,991 shares of the company's stock, valued at approximately $2,358,014.08. This represents a 5.16 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Howard Horn sold 1,785 shares of the firm's stock in a transaction that occurred on Thursday, March 6th. The shares were sold at an average price of $40.40, for a total value of $72,114.00. Following the completion of the sale, the chief financial officer now directly owns 106,169 shares of the company's stock, valued at approximately $4,289,227.60. The trade was a 1.65 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 124,643 shares of company stock worth $5,256,268 over the last ninety days. Corporate insiders own 5.50% of the company's stock.

Ultragenyx Pharmaceutical Trading Down 0.3 %

RARE traded down $0.11 during trading on Thursday, hitting $38.88. The stock had a trading volume of 258,333 shares, compared to its average volume of 816,009. The firm has a market cap of $3.65 billion, a PE ratio of -6.16 and a beta of 0.61. Ultragenyx Pharmaceutical Inc. has a 12 month low of $29.59 and a 12 month high of $60.37. The company has a 50 day simple moving average of $37.54 and a 200-day simple moving average of $43.38.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last issued its earnings results on Thursday, February 13th. The biopharmaceutical company reported ($1.39) earnings per share for the quarter, missing the consensus estimate of ($1.32) by ($0.07). Ultragenyx Pharmaceutical had a negative net margin of 101.60% and a negative return on equity of 193.80%. The business had revenue of $164.88 million for the quarter, compared to analyst estimates of $163.23 million. As a group, sell-side analysts anticipate that Ultragenyx Pharmaceutical Inc. will post -5.18 earnings per share for the current fiscal year.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.